Previous studies have shown that an anti‐TIM‐3 antibody, by binding to TIM‐3 expressed on tumour‐infiltrating lymphocytes (TILs) such as CD8+ T cells, reduces tumour growth via the induction of cytotoxic T‐cell‐mediated tumour cell lysis.58 Here, HAVCR2 is linked to neoplasm.